"Revolutionary Leap" on HIV Frontier: U.S. Greenlights New Prevention Drug
Approval granted in the U.S. for novel HIV preventive medication
Get the scoop, share on your fav socials! 👩🔬💉
A groundbreaking drug in the relentless battle against immune deficiency disease AIDS just scored the green light in the USA. On a monumental day last Wednesday (local time), U.S. drug regulatory body FDA greenlit Lenacapavir, developed by Gilead Sciences. Clinical trials revealed that Lenacapavir offers protection against HIV by an astounding 99.9%, rivaling vaccine efficiency. What distinguishes Lenacapavir is its requirement for mere two injections annually, unlike previously available HIV meds that demanded daily intake.
"Today marks a watershed moment in the years-long struggle against HIV," proclaimed Gilead CEO Daniel O'Day.
The drug's creators launched two extensive trials involving over 4,000 participants. Out of the pool, only two participants fell ill, showcasing the drug's efficacy. Reported side effects included pain at injection sites, headaches, and nausea. With a hefty price tag of $28,000 (approximately €24,000) per person per year, Lenacapavir presents an initial high cost as a preventative measure. Experts estimate production costs to be around $40.
Looking ahead to October 2024, Gilead announced licensing agreements with six generic manufacturers to produce and distribute Lenacapavir in low-income countries. Critics, however, point out that millions of HIV-infected individuals reside in countries where a more budget-friendly version of Lenacapavir won't be available in the immediate future.
🔑 Insights:
- Gilead's Lenacapavir received U.S. FDA approval in June 2025 for pre-exposure prophylaxis (PrEP), making it the first long-lasting injectable HIV prevention drug available in the U.S.
- Regulatory approvals in the European Union are expected in 2025, with the World Health Organization (WHO) set to release guidelines for Lenacapavir's use by July 2025.
- To make Lenacapavir affordable in low-income countries, Gilead has signed royalty-free licensing agreements with six generic pharmaceutical manufacturers. These licenses cover 120 primarily low- and lower-middle-income countries, enabling the supply of low-cost generic versions of the drug.
- Access is limited by the restrictions on geographical coverage and the lack of collaboration with the Medicines Patent Pool. Patent issues could also delay or restrict global access until patent challenges are settled.
- The community policy should address the affordability of the new HIV prevention drug, Lenacapavir, especially for individuals in low-income countries.
- In the realm of health-and-wellness, Lenacapavir's revolutionary preventative properties could significantly impact medical-conditions such as HIV and AIDS.
- Fitness-and-exercise, mental-health, and nutrition are important aspects of overall health that should be considered in conjunction with the use of therapies-and-treatments like Lenacapavir.
- Employment policies should consider accommodations for those who may experience side effects from Lenacapavir, such as pain at injection sites, headaches, and nausea.
